Oliver Grottke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2740706/publications.pdf

Version: 2024-02-01

89 papers	1,743 citations	304368 22 h-index	315357 38 g-index
90 all docs	90 docs citations	90 times ranked	1755 citing authors

#	Article	IF	Citations
1	Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood, 2011, 118, 1943-1951.	0.6	119
2	Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thrombosis and Haemostasis, 2015, 113, 728-740.	1.8	95
3	Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Critical Care, 2014, 18, R27.	2.5	89
4	Prothrombin Complex Concentrates in Trauma and Perioperative Bleeding. Anesthesiology, 2015, 122, 923-931.	1.3	88
5	The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2018, 26, 20.	1.1	64
6	Effects of different fibrinogen concentrations on blood losss and coagulation parameters in a pig model of coagulopathy with blunt liver injury. Critical Care, 2010, 14, R62.	2.5	63
7	Diagnosis and treatment of peripartum bleeding. Journal of Perinatal Medicine, 2008, 36, 467-78.	0.6	58
8	Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation. Journal of the American College of Cardiology, 2015, 66, 1518-1519.	1.2	55
9	Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model. Anesthesiology, 2015, 123, 1350-1361.	1.3	52
10	Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thrombosis and Haemostasis, 2016, 115, 271-284.	1.8	49
11	Cortisol and alpha-amylase as stress response indicators during pre-hospital emergency medicine training with repetitive high-fidelity simulation and scenarios with standardized patients. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2015, 23, 31.	1.1	46
12	Impact of Direct Oral Anticoagulants in Patients With Hip Fractures. Journal of Orthopaedic Trauma, 2019, 33, e8-e13.	0.7	43
13	Thrombin Generation Capacity of Prothrombin Complex Concentrate in an In Vitro Dilutional Model. PLoS ONE, 2013, 8, e64100.	1.1	42
14	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Critical Care, 2016, 20, 115.	2.5	40
15	Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia. Thrombosis and Haemostasis, 2011, 106, 724-733.	1.8	35
16	Direct Oral Anticoagulants in Emergency Trauma Admissions. Deutsches Ärzteblatt International, 2016, 113, 575-82.	0.6	35
17	Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects. American Journal of Medicine, 2016, 129, S64-S72.	0.6	34
18	Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial. Sports Medicine, 2016, 46, 1753-1766.	3.1	30

#	Article	IF	Citations
19	Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. American Journal of Emergency Medicine, 2016, 34, 26-32.	0.7	30
20	Role of extracorporeal membrane oxygenation in critically Ill COVIDâ€19 patients and predictors of mortality. Artificial Organs, 2021, 45, E158-E170.	1.0	30
21	Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays. Clinics in Laboratory Medicine, 2014, 34, 479-501.	0.7	29
22	Fibrinogen Supplementation and Its Indications. Seminars in Thrombosis and Hemostasis, 2020, 46, 038-049.	1.5	26
23	Perioperatively acquired disorders of coagulation. Current Opinion in Anaesthesiology, 2015, 28, 113-122.	0.9	24
24	Toward a Long-Term Artificial Lung. ASAIO Journal, 2020, 66, 847-854.	0.9	23
25	The thrombotic risk of spaceflight: has a serious problem been overlooked for more than half of a century?. European Heart Journal, 2021, 42, 97-100.	1.0	22
26	Microfluidic cell sorting: Towards improved biocompatibility of extracorporeal lung assist devices. Scientific Reports, 2018, 8, 8031.	1.6	21
27	Effect of TachoSil in a Coagulopathic Pig Model with Blunt Liver Injuries. Journal of Surgical Research, 2011, 171, 234-239.	0.8	20
28	The relevance of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentration for postoperative infections and postoperative organ dysfunctions in cardiac surgery patients: The eVIDenCe study. Clinical Nutrition, 2019, 38, 2756-2762.	2.3	20
29	Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma. Anesthesiology, 2017, 127, 852-861.	1.3	19
30	Pre-hospital plasma transfusion: a valuable coagulation support or an expensive fluid therapy?. Critical Care, 2019, 23, 238.	2.5	19
31	In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 591-599.e4.	0.4	19
32	Activated recombinant factor VII (rFVIIa). Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2010, 24, 95-106.	1.7	18
33	Prothrombin Complex Concentrate-induced Disseminated Intravascular Coagulation Can Be Prevented by Coadministering Antithrombin in a Porcine Trauma Model. Anesthesiology, 2019, 131, 543-554.	1.3	18
34	Thromboembolic and Bleeding Events in COVID-19 Patients receiving Extracorporeal Membrane Oxygenation. Thoracic and Cardiovascular Surgeon, 2021, 69, 526-536.	0.4	18
35	Use of blood and blood products in trauma. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2007, 21, 257-270.	1.7	17
36	Improving Hemocompatibility: How Can Smart Surfaces Direct Blood To Fight against Thrombi. ACS Applied Materials & Interfaces, 2021, 13, 11696-11707.	4.0	15

#	Article	IF	Citations
37	Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury. Anesthesia and Analgesia, 2016, 123, 38-48.	1.1	14
38	Transient or extended reversal of apixaban anticoagulation by andexanetÂalfa is equally effective in a porcine polytrauma model. British Journal of Anaesthesia, 2019, 123, 186-195.	1.5	14
39	Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. Anesthesiology, 2019, 131, 1153-1165.	1.3	14
40	Antifouling Microparticles To Scavenge Lipopolysaccharide from Human Blood Plasma. Biomacromolecules, 2019, 20, 959-968.	2.6	13
41	Sufficient Thrombin Generation Despite 95% Hemodilution: An In Vitro Experimental Study. Journal of Clinical Medicine, 2020, 9, 3805.	1.0	13
42	Coagulation management. Current Opinion in Critical Care, 2012, 18, 641-646.	1.6	12
43	Tissue oxygen saturation as an early indicator of delayed lactate clearance after cardiac surgery: a prospective observational study. BMC Anesthesiology, 2015, 15, 158.	0.7	12
44	Twelve Hours In Vitro Biocompatibility Testing of Membrane Oxygenators. ASAIO Journal, 2015, 61, 548-555.	0.9	12
45	Automatic Control of Venoâ€Venous Extracorporeal Lung Assist. Artificial Organs, 2016, 40, 992-998.	1.0	12
46	Effects of Fibrinogen Concentrate on Thrombin Generation, Thromboelastometry Parameters, and Laboratory Coagulation Testing in a 24-Hour Porcine Trauma Model. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 749-759.	0.7	12
47	The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 724-733.	0.7	12
48	Fibrinogen Concentrate Does Not Suppress Endogenous Fibrinogen Synthesis in a 24-hour Porcine Trauma Model. Anesthesiology, 2014, 121, 753-764.	1.3	12
49	Nonsurgical Techniques to Control Massive Bleeding. Anesthesiology Clinics, 2013, 31, 41-53.	0.6	11
50	Idarucizumab in major trauma patients: a single centre real life experience. European Journal of Trauma and Emergency Surgery, 2021, 47, 589-595.	0.8	11
51	Reversal of Apixaban Anticoagulation with Reduced Doses of Andexanet Alfa in a Porcine Polytrauma Model. Blood, 2018, 132, 2456-2456.	0.6	11
52	Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotProÂ® Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients. Journal of Clinical Medicine, 2021, 10, 3476.	1.0	10
53	Survival of HeartMate II Patients Despite Cessation of Anticoagulationã€€â€• Outcomes and Hemostatic Analysis â€•. Circulation Journal, 2018, 82, 1309-1318.	0.7	9
54	Outcomes of Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome in COVID-19 Patients: A Propensity-Matched Analysis. Journal of Clinical Medicine, 2021, 10, 2547.	1.0	9

#	Article	IF	Citations
55	Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal Model. Anesthesiology, 2021, 135, 673-685.	1.3	9
56	Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. Thrombosis and Haemostasis, 2022, 122, 552-559.	1.8	8
57	Influence of the bimanual frame of reference with haptics for unimanual interaction tasks in virtual environments. , 2011, , .		7
58	Fibrin patch in a pig model with blunt liver injury under severe hypothermia. Journal of Surgical Research, 2014, 187, 616-624.	0.8	7
59	Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia. PLoS ONE, 2015, 10, e0113979.	1.1	6
60	Coagulation factor concentrates and point-of-care coagulation monitoring: both might be essential for optimal treatment of trauma-induced coagulopathy. Lancet Haematology,the, 2017, 4, e246-e247.	2.2	6
61	The Reversal of Direct Oral Anticoagulants in Animal Models. Shock, 2017, 48, 144-158.	1.0	5
62	Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding. Thrombosis and Haemostasis, 2017, 117, 1370-1378.	1.8	5
63	Plasmaâ€derived Factorâ€‰X therapy for treatment of intracranial bleeding in a patient with Factorâ€‰X deficiency: a case report. Transfusion, 2019, 59, 2228-2233.	0.8	5
64	Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma. Transfusion, 2019, 59, 1376-1387.	0.8	5
65	Mechanistic Differences of Prothrombin Complex Concentrate and Idarucizumab in a Trauma Model Under Dabigatran Anticoagulation. Blood, 2015, 126, 1128-1128.	0.6	5
66	Interactive Hemocompatible Nanocoating to Prevent Surfaceâ€Induced Coagulation in Medical Devices. Advanced Materials Interfaces, 2022, 9, .	1.9	5
67	The use of coagulation factor concentrates for perioperative bleeding management â€“ a global perspective. Transfusion, 2020, 60, 663-666.	0.8	4
68	High Interleukin-6 Plasma Concentration upon Admission Is Predictive of Massive Transfusion in Severely Injured Patients. Journal of Clinical Medicine, 2021, 10, 2268.	1.0	4
69	Extended Coagulation Profiling in Isolated Traumatic Brain Injury: A CENTER-TBI Analysis. Neurocritical Care, 2022, 36, 927-941.	1.2	4
70	Septic porcine blood does not further activate coagulation duringin vitromembrane oxygenation. European Journal of Cardio-thoracic Surgery, 2017, 51, ezw345.	0.6	3
71	Extracorporeal membrane oxygenation in patients with COVID-19: 1-year experience. Journal of Thoracic Disease, 2021, 13, 5911-5924.	0.6	3
72	Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. Neurological Research and Practice, 2022, 4, 16.	1.0	3

#	Article	IF	Citations
73	Visualization of Fibrinogen-Dependent Thrombus Formation*. Critical Care Medicine, 2013, 41, 2661-2662.	0.4	2
74	Coagulation management for a caesarean delivery in a mother with severe homozygous Factor V deficiency. Journal of Clinical Anesthesia, 2021, 74, 110402.	0.7	2
75	Comparison of Second and First Generation of Andexanet Alfa in a Porcine Polytrauma Model with Apixaban Anticoagulation. Blood, 2018, 132, 3778-3778.	0.6	2
76	Ex Vivo Prothrombin Complex Concentrates and a Specific Antidote Are Effective In Reversing Dabigatran-Induced Coagulopathy In Pigs. Blood, 2013, 122, 2387-2387.	0.6	2
77	Reply to Faraoni D, Fengerâ€Eriksen C, Gillard S etÂal. Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. Paediatric Anaesthesia, 2015, 25, 646-647.	0.6	1
78	Resuscitation With Different Volume Expanders Does Not Influence Coagulation After Antidoting Dabigatran With Its Specific Fab In a Pig Model Of Hemorrhagic Shock. Blood, 2013, 122, 3649-3649.	0.6	1
79	Reversal of Trauma-Induced Bleeding and Anticoagulation with a Dabigatran-Specific Antidote (idarucizumab) As Assessed By Shed and Washed Blood Tests in a Pig Model of Supratherapeutic Anticoagulation and Trauma. Blood, 2014, 124, 4268-4268.	0.6	1
80	Re: Three versus four-factor prothrombin complex concentrates for â€œfactor-basedâ€•resuscitation in a porcine hemorrhagic shock model. Journal of Trauma and Acute Care Surgery, 2018, 84, 217-217.	1.1	0
81	Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution. PLoS ONE, 2019, 14, e0209350.	1.1	0
82	Response to Wirtz et al: The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients. Transfusion, 2021, 61, 991-992.	0.8	0
83	Thrombin Generation Capacity of Prothrombin Complex Concentrate in an in Vitro Dilutional Model. Blood, 2012, 120, 4380-4380.	0.6	0
84	Perioperative Management. , 2014, , 13-28.		0
85	Prothrombin Complex Concentrate in Combination with Fibrinogen Plus Tranexamic Acid Is More Effective Than Mono-Therapy with Prothrombin Complex Concentrate in a Dabigatran Anticoagulation Experimental Polytrauma Model. Blood, 2014, 124, 346-346.	0.6	0
86	Prothrombin Complex Concentrate or Idarucizumab in a Multimodal Hemostatic Approach with Tranexamic Acid and Fibrinogen for the Acute Reversal of Dabigatran. Blood, 2015, 126, 2275-2275.	0.6	0
87	Rekombinanter Faktor VIIa. , 2016, , 197-210.		0
88	Markers of Thromboembolic Risk Were Insignificantly Affected By Either Intraosseous or Intravenous Idarucizumab in a Dabigatran-Anticoagulated Porcine Polytrauma Model. Blood, 2016, 128, 2623-2623.	0.6	0
89	Prothrombin complex concentrate (PCC) for the treatment of coagulopathy associated with massive bleeding. Wiener Klinische Wochenschrift, 2010, 122 Suppl 5, S23-4.	1.0	0